Jagiellonian University

uj.edu.pl

Total trials

155

Active

31

Phase 3

6

Total enrollment

77,675

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 11 of 11 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Nebivolol1
FLOT + HIPEC + Surgery1
FLOT + Surgery1
Ivabradine1
noradrenaline infusion for management blood pressure1
standard blood pressure management1
Chemoimmunotherapy1
Celiac Plexus Block1
ESP block1
Lidacaine1
Balanced anesthesia with opioids1

Next readouts

  • 2025-04-30
  • 2026-01
  • 2026-09-30
  • 2026-12-31
  • 2027-06-30
  • 2027-12-31
  • 2029-01-01

Top conditions

  • Gastric Cancer5
  • Endometriosis4
  • Infertility Unexplained4
  • Rectal Cancer4
  • Goiter3
  • Neuroendocrine Tumors3
  • Anovulation3
  • Pheochromocytoma3

Frequently asked questions about Jagiellonian University

How many clinical trials does Jagiellonian University have on ClinicalTrials.gov?
Jagiellonian University is listed as the lead sponsor on 155 clinical trials in ClinicalTrials.gov, 31 of which are currently active (recruiting, enrolling, or ongoing).
How many of Jagiellonian University's trials are in Phase 3?
6 of Jagiellonian University's trials are in Phase 3, spread across 11 active drug programs.
What therapeutic areas does Jagiellonian University focus on?
Jagiellonian University's most-studied conditions on ClinicalTrials.gov are Gastric Cancer, Endometriosis, Infertility Unexplained, Rectal Cancer, Goiter.
When are Jagiellonian University's next clinical trial readouts?
Jagiellonian University has 7 upcoming primary-completion readouts tracked here; the soonest is “Ivabradine for Prevention of Myocardial Injury After Noncardiac Surgery Trial (PREVENT-MINS)”, expected around 2025-04-30.